Weinman, Jason P. http://orcid.org/0000-0001-6540-3757
Mong, David A.
Malone, LaDonna J.
Ivy, Dunbar D.
Deterding, Robin R.
Galambos, Csaba
Article History
Received: 22 December 2021
Revised: 10 May 2022
Accepted: 31 May 2022
First Online: 11 June 2022
Declarations
:
: Dr. Weinman is a reviewer of imaging studies in fibrosing lung disease for Parexel/Calyx and is on the advisory board and receives non-financial support from Boehringer Ingelheim for fibrosing lung disease. The University of Colorado School of Medicine has received consulting fees for Dr. Ivy from Actelion, Bayer, Gilead, Eli Lilly, Pfizer and United Therapeutics. Dr. Deterding is chief executive officer and founder of NowVitals Inc., founder and chief medical officer of Earables, coordinating investigator and consultant for Boehringer Ingelheim, and founder and consultant for EvoEndo. The other authors have nothing to disclose.